“We’re discussing it, but we haven’t signed a contract yet,” said Stephan Bansel of Cambridge, Massachusetts, where the company is based.
Bancel, a 48-year-old Frenchman, runs a small company founded from 2011 to 2010.
After Pfizer and Biotech announced the vaccine’s success, the company announced on Monday that its vaccine had shown almost (95%) efficacy in clinical trials.
Both vaccines are expected to receive marketing approvals from the United States, Europe and other authorities in the coming weeks.
Bancel had already announced a “advanced discussion” with the European Commission on August 24 to purchase 80 million doses of the vaccine, but no solid promise has been signed since then.
Stefan Bansel said, “There are a lot of administrative issues, files and other things, and there is a lot of coordination between countries. It is difficult to manage when we have 27 countries.
Source link
